Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the confusion about the optimal microneedling depth and frequency for hair growth, and when to apply treatments like minoxidil. A reply suggests the best method is using a 1.25mm depth every 7 days with a specific device, holding it for 10 seconds to stimulate hair growth.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

A user's experience with taking dutasteride and minoxidil for hair loss, with other users providing advice to continue treatment for at least 12 months and including dermarolling as well as dietary changes.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

The user experienced hair regrowth using finasteride for 1.5 years and minoxidil foam for 4 months, starting at age 17. They reported no side effects and noted that finasteride helped maintain existing hair while minoxidil contributed to regrowth.

The user has been using oral finasteride, topical minoxidil, a derma roller, and root activating shampoo for hair regrowth, seeing positive results without side effects. They apply minoxidil after using a 1.5mm derma roller and are considering switching to ketoconazole shampoo.

A 25-year-old male shared his 10-month hair regrowth progress using oral finasteride, oral minoxidil, a 5% liquid spray, keto shampoo, and supplements like vitamin D, biotin, zinc, and magnesium. He reported improved hair thickness and health, especially on the sides, and is considering starting microneedling.

The user experienced significant hair regrowth using oral minoxidil for 2 years and finasteride for 1.5 years, with no side effects reported. They are considering derma rolling and possibly a hair transplant in the future.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

The user experienced significant hair regrowth after six months of using oral Finasteride (1mg) and Minoxidil (2.5mg) nightly, with no side effects. They also used dermastamping and biotin, emphasizing consistency and a healthy lifestyle.

A 24-year-old shared six months of progress using 1mg finasteride daily and topical minoxidil twice daily, reporting improved hairline and temples with no side effects. The user experienced initial shedding but noted significant regrowth and no erectile dysfunction issues.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

A 14-year-old is experiencing significant hair loss and was prescribed Aminexil by a dermatologist. They are concerned about potential side effects.

The conversation discusses unconventional and satirical ideas for hair regrowth, including using umbilical cord cells, stem cells, and other humorous suggestions. It concludes with recommendations for more traditional methods like hair transplants or hair systems.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

A user shared progress pictures showing significant hair regrowth after 134 days on oral finasteride and 59 days on topical minoxidil foam. They reported mild side effects initially but are now satisfied with the results.

A 30-year-old male shares his 3-month hair regrowth progress using oral finasteride daily, topical minoxidil twice daily, and Nizoral shampoo. He considers switching to oral minoxidil but is unsure due to positive results with the current regimen.

The conversation is about hair regrowth using topical minoxidil, microneedling, and vitamin supplements. The user is hesitant to use DHT blockers like finasteride due to concerns about hormonal side effects.

The user experienced positive hair growth results after a year of using finasteride, initially taking 1mg daily but switching to a Monday, Wednesday, Friday schedule due to side effects like erectile dysfunction and watery semen. The side effects improved after switching to the reduced schedule, with normal erections returning within a month.

The user has been on finasteride and minoxidil since 2020 and increased dutasteride and minoxidil doses in June 2024, but still experiences hair loss. Despite trying pyrilutamide without success, opinions vary on whether the hair loss is significant, with some suggesting it might be due to lighting, angles, or a regular shedding cycle.